PTPRA

Summary

PTPRA (protein tyrosine phosphatase receptor type A, HGNC:9664) is a protein-coding gene on chromosome 20p13, encoding Receptor-type tyrosine-protein phosphatase alpha (P18433). Tyrosine protein phosphatase which is involved in integrin-mediated focal adhesion formation.

The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP contains an extracellular domain, a single transmembrane segment and two tandem intracytoplasmic catalytic domains, and thus represents a receptor-type PTP. This PTP has been shown to dephosphorylate and activate Src family tyrosine kinases, and is implicated in the regulation of integrin signaling, cell adhesion and proliferation. Three alternatively spliced variants of this gene, which encode two distinct isoforms, have been reported.

Source: NCBI Gene 5786 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 197 total — 1 pathogenic, 5 likely-pathogenic
• GTEx eGene: eQTL in 21 tissues, sQTL in 7 (q < 0.05)
• Constraint (gnomAD): pLI 1.00 (loss-of-function intolerant), LOEUF 0.26 (highly constrained)
• MANE Select transcript: NM_001385305
• Notable: 197 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9664
Approved symbol	PTPRA
Name	protein tyrosine phosphatase receptor type A
Location	20p13
Locus type	gene with protein product
Status	Approved
Aliases	LRP, HLPR, HPTPA, RPTPA
Ensembl gene	ENSG00000132670
Ensembl biotype	protein_coding
OMIM	176884
Entrez	5786

Gene structure

Transcript identifiers

Ensembl transcripts: 90 — 79 protein_coding, 11 nonsense_mediated_decay

MANE Select: ENST00000399903

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 2, TSL 5: 5

ENST00000399903, ENST00000216877, ENST00000318266, ENST00000356147, ENST00000430705, ENST00000431048, ENST00000455631, ENST00000876898, ENST00000876899, ENST00000876900, ENST00000876901, ENST00000876902, ENST00000876903, ENST00000876904, ENST00000876905, ENST00000876906, ENST00000876907, ENST00000876908, ENST00000876909, ENST00000876910, ENST00000876911, ENST00000876912, ENST00000876913, ENST00000876914, ENST00000876915, ENST00000876916, ENST00000876917, ENST00000876918, ENST00000876919, ENST00000876920, ENST00000876921, ENST00000876922, ENST00000876923, ENST00000876924, ENST00000876925, ENST00000876926, ENST00000876927, ENST00000876928, ENST00000876929, ENST00000876930, ENST00000876931, ENST00000876932, ENST00000876933, ENST00000911872, ENST00000911873, ENST00000911874, ENST00000911875, ENST00000911877, ENST00000911878, ENST00000911880, ENST00000911881, ENST00000911883, ENST00000911885, ENST00000911887, ENST00000970270, ENST00000970271, ENST00000970272, ENST00000970273, ENST00000970274, ENST00000970275, ENST00000970276, ENST00000970277, ENST00000970278, ENST00000970279, ENST00000970280, ENST00000970281, ENST00000970282, ENST00000970283, ENST00000970284, ENST00000970285, ENST00000970286, ENST00000970287, ENST00000970288, ENST00000970289, ENST00000970290, ENST00000970291, ENST00001004875, ENST00001036176, ENST00001036177, ENST00001036179, ENST00001036180, ENST00001036182, ENST00001036183, ENST00001036185, ENST00001036186, ENST00001036187, ENST00001060950, ENST00001109012, ENST00001109013, ENST00001132615

RefSeq mRNA: 27 — MANE Select: NM_001385305 NM_001385302, NM_001385303, NM_001385304, NM_001385305, NM_001385306, NM_001385307, NM_001385308, NM_001385310, NM_001385311, NM_001385312, NM_001385313, NM_001385314, NM_001385315, NM_001385316, NM_001385317, NM_001385318, NM_001385319, NM_001385320, NM_001385321, NM_001388320, NM_001388321, NM_001388322, NM_001388323, NM_001388324, NM_002836, NM_080840, NM_080841

CCDS: CCDS13038, CCDS13039

Canonical transcript exons

ENST00000399903 — 24 exons

Exon	Start	End
ENSE00000332881	2988338	2988474
ENSE00000656611	3005056	3005146
ENSE00000656613	3015849	3015885
ENSE00000656617	3022054	3022220
ENSE00000656629	3022689	3022824
ENSE00000656630	3024472	3024621
ENSE00000656631	3026687	3026780
ENSE00000656633	3027121	3027197
ENSE00000656634	3027707	3027841
ENSE00000656635	3035585	3035710
ENSE00000656636	3035790	3035941
ENSE00000656637	3037154	3037289
ENSE00000858706	3021309	3021428
ENSE00001043919	2975215	2975241
ENSE00001163806	3007344	3007420
ENSE00001312856	2947982	2948024
ENSE00001484692	2873481	2873760
ENSE00001746935	3017816	3017913
ENSE00003008107	2988032	2988105
ENSE00003597267	2923207	2923285
ENSE00003603687	2964272	2964350
ENSE00003786041	2986765	2986849
ENSE00003786244	2964861	2965202
ENSE00003917099	3038059	3038669

Expression profiles

Bgee: expression breadth ubiquitous, 295 present calls, max score 98.99.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 39.9218 / max 286.2854, expressed in 1823 samples.

Highest expression (Bgee): calcaneal tendon, ventricular zone, ganglionic eminence, frontal lobe, cortical plate.

Genetic regulation across tissues (GTEx eQTL / sQTL)

PTPRA is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 21 tissues and its splicing (sQTL) in 7 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 28 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Testis	sqtl	3.7e-34	-0.93	20:3008284:C:A
Artery Tibial	eqtl	5.8e-07	+0.15	20:2913666:CTTATT:C
Adipose Subcutaneous	eqtl	1.2e-05	-0.17	20:2820763:G:A
Colon Transverse	eqtl	1.7e-05	-0.35	20:3059008:G:A
Whole Blood	eqtl	1.0e-04	-0.11	20:3020700:G:C
Cells Cultured fibroblasts	eqtl	1.8e-04	+0.16	20:2857667:A:G
Esophagus Mucosa	eqtl	1.0e-03	+0.12	20:2913666:CTTATT:C
Adipose Visceral Omentum	eqtl	1.7e-03	-0.14	20:2820763:G:A
Skin Not Sun Exposed Suprapubic	sqtl	1.8e-03	-1.37	20:3173063:G:A
Brain Nucleus accumbens basal ganglia	eqtl	3.8e-03	+0.44	20:2873551:C:A
Brain Caudate basal ganglia	sqtl	5.2e-03	-0.50	20:2913666:CTTATT:C
Ovary	sqtl	5.4e-03	-0.37	20:2980287:G:A
Breast Mammary Tissue	eqtl	6.3e-03	+0.12	20:2861456:T:C
Small Intestine Terminal Ileum	eqtl	7.7e-03	+0.79	20:1996279:C:T
Nerve Tibial	eqtl	9.2e-03	+0.10	20:2861456:T:C
Brain Cortex	eqtl	1.0e-02	+0.42	20:2873551:C:A
Esophagus Gastroesophageal Junction	eqtl	1.2e-02	+0.43	20:1881990:G:A
Brain Amygdala	eqtl	1.4e-02	+0.41	20:2873551:C:A
Adipose Subcutaneous	sqtl	1.5e-02	-0.30	20:3031773:C:CTGTT
Brain Cerebellar Hemisphere	eqtl	1.5e-02	+0.59	20:2772049:A:T

FANTOM5 promoters

showing 10 of 12 alternative TSS:

Promoter ID	TPM avg	Samples expressed
183190	70.3569	1826
98879	39.9218	1823
98877	8.4013	1738
98885	7.4934	1299
98892	5.5499	977
98889	1.4921	738
98876	0.9251	487
98886	0.7310	201
98884	0.6302	389
98887	0.4037	210

Top tissues by expression

showing 100 of 300 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	98.99	gold quality
ventricular zone	UBERON:0003053	97.62	gold quality
ganglionic eminence	UBERON:0004023	97.25	gold quality
right frontal lobe	UBERON:0002810	97.19	gold quality
cortical plate	UBERON:0005343	96.98	gold quality
prefrontal cortex	UBERON:0000451	96.93	gold quality
nucleus accumbens	UBERON:0001882	96.76	gold quality
right hemisphere of cerebellum	UBERON:0014890	96.70	gold quality
cerebellar hemisphere	UBERON:0002245	96.69	gold quality
amygdala	UBERON:0001876	96.67	gold quality
cerebellar cortex	UBERON:0002129	96.66	gold quality
cingulate cortex	UBERON:0003027	96.55	gold quality
anterior cingulate cortex	UBERON:0009835	96.52	gold quality
caudate nucleus	UBERON:0001873	96.34	gold quality
Brodmann (1909) area 9	UBERON:0013540	96.33	gold quality
lateral nuclear group of thalamus	UBERON:0002736	96.32	gold quality
corpus callosum	UBERON:0002336	96.30	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	96.04	gold quality
hypothalamus	UBERON:0001898	95.93	gold quality
cerebellum	UBERON:0002037	95.93	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	95.92	gold quality
putamen	UBERON:0001874	95.91	gold quality
spinal cord	UBERON:0002240	95.82	gold quality
neocortex	UBERON:0001950	95.65	gold quality
frontal cortex	UBERON:0001870	95.60	gold quality
frontal lobe	UBERON:0016525	95.60	gold quality
temporal lobe	UBERON:0001871	95.58	gold quality
telencephalon	UBERON:0001893	95.52	gold quality
paraflocculus	UBERON:0005351	95.38	gold quality
Ammon’s horn	UBERON:0001954	95.33	gold quality
cerebral cortex	UBERON:0000956	95.32	gold quality
forebrain	UBERON:0001890	95.32	gold quality
central nervous system	UBERON:0001017	95.27	gold quality
substantia nigra pars reticulata	UBERON:0001966	95.26	gold quality
tendon	UBERON:0000043	95.25	gold quality
brain	UBERON:0000955	95.25	gold quality
gall bladder	UBERON:0002110	95.15	gold quality
superior vestibular nucleus	UBERON:0007227	95.04	gold quality
dorsal plus ventral thalamus	UBERON:0001897	94.87	gold quality
lateral globus pallidus	UBERON:0002476	94.83	gold quality
frontal pole	UBERON:0002795	94.79	gold quality
ventral tegmental area	UBERON:0002691	94.73	gold quality
substantia nigra pars compacta	UBERON:0001965	94.69	gold quality
subthalamic nucleus	UBERON:0001906	94.60	gold quality
midbrain	UBERON:0001891	94.33	gold quality
middle frontal gyrus	UBERON:0002702	94.33	gold quality
islet of Langerhans	UBERON:0000006	94.32	gold quality
substantia nigra	UBERON:0002038	94.32	gold quality
entorhinal cortex	UBERON:0002728	94.21	gold quality
rectum	UBERON:0001052	94.04	gold quality
CA1 field of hippocampus	UBERON:0003881	93.97	gold quality
Brodmann (1909) area 10	UBERON:0013541	93.88	gold quality
smooth muscle tissue	UBERON:0001135	93.87	gold quality
ectocervix	UBERON:0012249	93.78	gold quality
right coronary artery	UBERON:0001625	93.75	gold quality
skin of leg	UBERON:0001511	93.73	gold quality
endocervix	UBERON:0000458	93.67	gold quality
granulocyte	CL:0000094	93.63	gold quality
medulla oblongata	UBERON:0001896	93.59	gold quality
body of uterus	UBERON:0009853	93.53	gold quality
stromal cell of endometrium	CL:0002255	93.51	gold quality
right lung	UBERON:0002167	93.51	gold quality
adenohypophysis	UBERON:0002196	93.42	gold quality
popliteal artery	UBERON:0002250	93.39	gold quality
tibial artery	UBERON:0007610	93.39	gold quality
descending thoracic aorta	UBERON:0002345	93.36	gold quality
left ovary	UBERON:0002119	93.23	gold quality
skin of abdomen	UBERON:0001416	93.22	gold quality
globus pallidus	UBERON:0001875	93.18	gold quality
aorta	UBERON:0000947	93.12	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	93.10	gold quality
medial globus pallidus	UBERON:0002477	92.96	gold quality
thoracic aorta	UBERON:0001515	92.84	gold quality
nerve	UBERON:0001021	92.83	gold quality
tibial nerve	UBERON:0001323	92.83	gold quality
subcutaneous adipose tissue	UBERON:0002190	92.82	gold quality
orbitofrontal cortex	UBERON:0004167	92.82	gold quality
pituitary gland	UBERON:0000007	92.81	gold quality
ascending aorta	UBERON:0001496	92.77	gold quality
omental fat pad	UBERON:0010414	92.73	gold quality
peritoneum	UBERON:0002358	92.71	gold quality
left lobe of thyroid gland	UBERON:0001120	92.69	gold quality
left coronary artery	UBERON:0001626	92.63	gold quality
superior frontal gyrus	UBERON:0002661	92.57	gold quality
coronary artery	UBERON:0001621	92.56	gold quality
inferior vagus X ganglion	UBERON:0005363	92.49	gold quality
right ovary	UBERON:0002118	92.47	gold quality
thyroid gland	UBERON:0002046	92.45	gold quality
minor salivary gland	UBERON:0001830	92.24	gold quality
right lobe of thyroid gland	UBERON:0001119	92.21	gold quality
adipose tissue of abdominal region	UBERON:0007808	92.13	gold quality
left uterine tube	UBERON:0001303	92.11	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	92.11	gold quality
mucosa of stomach	UBERON:0001199	92.09	gold quality
monocyte	CL:0000576	92.06	gold quality
lower esophagus muscularis layer	UBERON:0035833	91.99	gold quality
lower esophagus	UBERON:0013473	91.98	gold quality
leukocyte	CL:0000738	91.97	gold quality
cerebellar vermis	UBERON:0004720	91.86	gold quality
zone of skin	UBERON:0000014	91.85	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.65
E-MTAB-2983	no	660.05

HPA expression

RNA tissue specificity: Low tissue specificity

showing 60 of 80 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Hippocampus	tissue	150.1	medium
Locus coeruleus	tissue	137.7
Postcentral gyrus	tissue	136.4
Caudate putamen	tissue	131.8
Frontal cortex	tissue	131.3
Nucleus accumbens	tissue	125.3
Prefrontal cortex	tissue	106.3
Cerebral cortex	tissue	106.3	medium
Motor cortex	tissue	101.1
Basal ganglia	tissue	99.6	medium
Hippocampal formation	tissue	99.6
Entorhinal cortex	tissue	96.0
Choroid plexus	tissue	95.8
Somatosensory cortex	tissue	95.6
Retrosplenial and cingulate cortex	tissue	92.7
Putamen	tissue	92.0
Temporal cortex	tissue	90.7
Retrosplenial cortex	tissue	90.6
Occipital cortex	tissue	87.1
Ventral forebrain	tissue	84.1
Insular cortex	tissue	82.9
Septum	tissue	82.5
Thalamus	tissue	82.3
Midbrain	tissue	78.0
Spinal cord	tissue	78.0
Parathyroid gland	tissue	77.6	not detected
Pons	tissue	76.3
Amygdala	tissue	76.2
Medulla oblongata	tissue	74.6
Corpus callosum	tissue	70.9
Substantia nigra	tissue	70.3
Superior colliculi	tissue	70.2
Hypothalamus	tissue	70.1
Periaqueductal gray	tissue	68.5
Thyroid gland	tissue	61.5	medium
Retina	tissue	57.5
Placenta	tissue	57.2	medium
Thymus	tissue	55.7
Olfactory bulb	tissue	53.7
Ovary	tissue	53.2	medium
Cervix	tissue	53.0	medium
Cerebellum	tissue	52.6	medium
Endometrium 1	tissue	50.0	medium
Fallopian tube	tissue	49.6	high
Smooth muscle	tissue	49.0	medium
Breast	tissue	44.5	medium
Urinary bladder	tissue	43.8	high
Prostate	tissue	43.6	medium
Esophagus	tissue	43.5	medium
Lung	tissue	43.0	medium
Adipose tissue	tissue	42.2	not detected
Tonsil	tissue	41.7	medium
Pituitary gland	tissue	41.6
Gallbladder	tissue	41.3	medium
Kidney	tissue	41.2	medium
Testis	tissue	41.0	medium
Seminal vesicle	tissue	39.7	medium
Colon	tissue	38.9	medium
Rectum	tissue	38.7	medium
Skin 1	tissue	37.6	medium

Brain sub-regions (HPA Brain Atlas): detected in 192; highest nTPM — Orbitofrontal gyrus, anterior (180.2), Posterior thalamic nucleus (170.3), Nucleus of the diagonal band (156.2), Hippocampus, CA1 (154.6), Temporal pole (151.6).

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): TP53, YY1

Functional genomics

gnomAD constraint: pLI 1, LOEUF 0.26, missense Z 3.35 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD)

ENST00000399903 splits into 4 regions with different missense tolerance; 0 are missense-constrained. Missense variants in a constrained region (low observed/expected) are more likely to be pathogenic. gnomAD

Region (GRCh38)	Missense obs / exp	o/e	Constrained
20:2,964,278–2,988,349	256 / 248.9	1.03	no
20:2,988,350–3,024,540	245 / 398.7	0.61	no
20:3,024,541–3,035,827	192 / 227.0	0.85	no
20:3,035,828–3,038,130	72 / 140.7	0.51	no

Literature-anchored findings (GeneRIF, showing 40)

• Physical and functional interactions between protein tyrosine phosphatase alpha, PI 3-kinase, and PKCdelta. (PMID:11676480)
• In entering mitosis the cell cycle-specific regulation of c-Src by RPTPalpha can occur by dephosphorylation of phospho-Tyr527 that activates c-Src in a reaction catalyzed by the transmembrane receptor-like protein tyrosine phosphatase RPTPalpha. (PMID:11796915)
• interactions between RPTP-domain1s and RPTP-domain 2s are a common but specific mechanism that is likely to be regulated- domain2s and the wedge structures are crucial determinants of binding specificity, thus regulating cross-talk between RPTPs (PMID:12376545)
• RPTPs have the capacity for inside-out signaling (PMID:12582170)
• This protein regulates nuclear translocation of ERK2 and can modulate megakaryocytic differentiation of K562 cells. (PMID:12592337)
• data suggest that receptor-like protein tyrosine phosphatase alpha acts as a receptor for Helicobacter pylori VacA toxin in G401 cells (PMID:12626515)
• Receptor protein tyrosine phosphatase alpha signaling has a role in androgen depletion-induced neuroendocrine differentiation of prostate tumor cells (PMID:14555984)
• These data reveal a functional relevance of PTP alpha for insulin secretion. (PMID:14592422)
• PTPRA and PTPRZ may have roles in gastric cancer progression including lymphovascular invasion and liver/peritoneal dissemination (PMID:16338072)
• the two splice variants of PTPalpha are expressed differentially and regulate c-Src activity in different ways. (PMID:17212655)
• siRNA-mediated suppression of protein tyrosine phosphatase alpha (PTP alpha) reduces Src activity 2 to 4-fold in breast, colon and other human cancer cell lines. (PMID:18183590)
• CD63 plays a role in the regulation of ROMK channels through its association with RPTPalpha, which in turn interacts with and activates Src family PTK, thus reducing ROMK activity. (PMID:18211905)
• This study showed that PTPalpha is required for remodeling of focal adhesion during cell spreading via a pathway involving Rac1. (PMID:18216165)
• report a statistically significant lower expression intensity of PTEN and HePTP (PMID:18728972)
• RPTPalpha plays a critical role in HCN channel function via tyrosine dephosphorylation (PMID:18768480)
• PTPalpha acts as an adaptor to mediate functional links between focal adhesions and the endoplasmic reticulum that enable IL-1-induced Ca2+ signaling. (PMID:19497848)
• force-responsive proteins such as RPTPalpha can influence cancer-cell behavior and identify potential targets for cancer therapy. (PMID:20208566)
• IL-1-induced signaling through focal adhesions leading to MMP3 release and interactions between SHP-2 and PTPalpha are dependent on the integrity of the catalytic domains of PTPalpha. (PMID:20472558)
• a novel role for E-loop residue Lys182 in enhancing HePTP catalytic activity through its interaction with Asp236 of the WPD loop was revealed. (PMID:21094165)
• the PTPalpha-mediated increase of NB-3 level at the cell surface represents a novel function of PTPalpha in NB-3 signaling in neural development (PMID:21622556)
• The transformed cells were tumourigenic in nude mice, suggesting that RPTPalpha245-induced activation of Src in the human tumours may have contributed to carcinogenesis. (PMID:21725282)
• convergent evidence reported here links RPTP to schizophrenia. (PMID:21831360)
• The extracellular proteolytic processing is a novel mechanism for PTPalpha regulation. (PMID:22647903)
• our results suggest that plasma PTPalpha and fibronectin may be associated with opisthorchiasis. (PMID:23029023)
• Results suggest that inhibition of PTPalpha can have a beneficial effect on HER2-positive breast cancers, but that inhibition of additional targets is needed to block breast tumorigenesis. (PMID:23318421)
• A single-nucleotide polymorphism (rs6138953) on the PTPRA gene in the 20p13 region was found to be associated with elevated fasting glucose level. (PMID:23487342)
• results suggest that PTPalpha links activation of epidermal growth factor receptor (EGFR) signaling with Src activation and may provide a novel therapeutic target for treatment of breast cancer. (PMID:23532252)
• new role for PTPalpha in the regulation of motility of mammary epithelial cells in response to ErbB2 activation. (PMID:24217252)
• recruited to epithelial adherens junctions for cadherin-dependent cell adhesion and tissue architecture formation (PMID:24652832)
• no evidence was seen for the association of rare, missense mutations in the PTPRA gene with schizophrenia or autism spectrum disorders (PMID:25393624)
• A receptor type-protein tyrosine phosphatase alpha-Src family kinase-Rap1 pathway was identified as responsible for recruiting myosin IIB to the zonula adherens in epithelial cells and supporting contractile tension. (PMID:25631816)
• Data indicate that scaffold protein RACK1 plays a role in IGF-1-mediated protein-tyrosine phosphatase alpha (PTPalpha) tyrosine phosphorylation in MCF-7 Cells. (PMID:25694432)
• VacA mediates CagA phosphorylation through RPTPalpha in AZ-521 cells. (PMID:27935824)
• Multivariate Cox regression analysis suggested that PTPRA expression was an independent prognostic factor in SCC patients. In the cellular models, PTPRA promotes SCC cell proliferation through modulating Src activation as well as cell cycle progression. In conclusion, higher PTPRA level was associated with worse prognosis of SCC patients and PTPRA could promote the cell cycle progression (PMID:28656243)
• Filtered data from WES, combined with in silico analyses revealed a novel heterozygous missense variant (NM_080841:c.1730C>G:p.T577R; exon18) in Protein tyrosine phosphatase, receptor type A (PTPRA 20p13) in an Indian family with schizophrenia. Screening for variants in this gene in the WES data of an independent schizophrenia cohort (n=350) of matched ethnicity, identified five additional rare missense variants. (PMID:30594456)
• circPTPRA suppresses EMT and metastasis of NSCLC cell lines by sponging miR-96-5p, which upregulates the downstream tumor suppressor RASSF8. (PMID:31160270)
• HePTP plays a key role in the metastasis of triple-negative breast cancer via activating Wnt/beta-catenin signaling. (PMID:31545274)
• miR-146a-5p may negatively regulate the PTPRA-SRC signaling to inhibit expression of fibrosis-related markers in irradiated and TGF-beta1-stimulated LX2 cells (PMID:31560641)
• Leukocyte common antigen-related receptor protein tyrosine phosphatases (LAR-RPTPs) are cell adhesion molecules involved in mediating neuronal development. The binding of LAR-RPTPs to extracellular ligands induces local clustering of LAR-RPTPs to regulate axon growth and synaptogenesis. LAR-RPTPs interact with synaptic liprin-alpha proteins via the two cytoplasmic phosphatase domains, D1 and D2. (PMID:31924785)
• RPTPalpha phosphatase activity is allosterically regulated by the membrane-distal catalytic domain. (PMID:32139509)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	ptpra	ENSDARG00000001769
mus_musculus	Ptpra	ENSMUSG00000027303
rattus_norvegicus	Ptpra	ENSRNOG00000021223

Paralogs (35): PTPRN (ENSG00000054356), PTPRU (ENSG00000060656), PTPN3 (ENSG00000070159), PTPN21 (ENSG00000070778), PTPN18 (ENSG00000072135), PTPN23 (ENSG00000076201), PTPRH (ENSG00000080031), PTPRC (ENSG00000081237), PTPN4 (ENSG00000088179), PTPRS (ENSG00000105426), PTPRZ1 (ENSG00000106278), PTPN5 (ENSG00000110786), PTPN6 (ENSG00000111679), PTPRB (ENSG00000127329), PTPN12 (ENSG00000127947), PTPRE (ENSG00000132334), PTPN22 (ENSG00000134242), PTPRF (ENSG00000142949), PTPN7 (ENSG00000143851), PTPRG (ENSG00000144724), PTPRJ (ENSG00000149177), PTPRO (ENSG00000151490), PTPN14 (ENSG00000152104), PTPRK (ENSG00000152894), PTPRR (ENSG00000153233), PTPRD (ENSG00000153707), PTPRN2 (ENSG00000155093), PTPN13 (ENSG00000163629), PTPN9 (ENSG00000169410), PTPRM (ENSG00000173482), PTPN2 (ENSG00000175354), PTPN11 (ENSG00000179295), PTPRT (ENSG00000196090), PTPN1 (ENSG00000196396), PTPN20 (ENSG00000204179)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:97808) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 14 distinct phenotype terms.

Mouse phenotype (MP)	Records
decreased anxiety-related response	1
decreased locomotor activity	1
abnormal spatial learning	1
increased startle reflex	1
abnormal parental behavior	1
abnormal postnatal growth/weight/body size	1
decreased vertical activity	1
abnormal cell adhesion	1
decreased susceptibility to injury	1
increased mean corpuscular hemoglobin	1
abnormal cell physiology	1
decreased prepulse inhibition	1
abnormal cerebral cortex pyramidal cell morphology	1
decreased grip strength	1

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Gallus gallus	Q90687	98.3%	Diamond
Bos taurus	A7MBJ4	95.7%	Diamond
Macaca nemestrina	O02695	94.4%	Diamond
Styela plicata	P28205	93.9%	Diamond
Aedes aegypti	A0A6I8TCE0	89.3%	Diamond
Culex quinquefasciatus	B0X4T2	89.3%	Diamond
Drosophila melanogaster	P16621	86.8%	Diamond
Drosophila virilis	Q24708	74.6%	Diamond
Microplitis demolitor bracovirus (isolate Webb)	Q5I154	100.0%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
C20orf141	protein-coding	128653
CPXM1	protein-coding	56265
VPS16	protein-coding	64601
PCED1A	protein-coding	64773
TMEM239	protein-coding	100288797
GNRH2	protein-coding	2797
MRPS26	protein-coding	64949
OXT	protein-coding	5020
AVP	protein-coding	551

Protein

Protein identifiers

Receptor-type tyrosine-protein phosphatase alpha — P18433 (reviewed: P18433)

All UniProt accessions (4): P18433, Q5JWG0, Q5JWG2, Q5JWG3

UniProt curated annotations — full annotation on UniProt →

Function. Tyrosine protein phosphatase which is involved in integrin-mediated focal adhesion formation. Following integrin engagement, specifically recruits BCAR3, BCAR1 and CRK to focal adhesions thereby promoting SRC-mediated phosphorylation of BRAC1 and the subsequent activation of PAK and small GTPase RAC1 and CDC42.

Subunit / interactions. Part of a complex comprised of PTPRA, BCAR1, BCAR3 (via SH2 domain), and SRC. Within the complex, interacts (when phosphorylated on Tyr-798) with BCAR3 (via SH2 domain). Interacts with GRB2.

Subcellular location. Cell membrane. Cell junction. Focal adhesion.

Post-translational modifications. Integrin binding to extracellular matrix induces phosphorylation at Tyr-798 which induces PTPRA localization and recruitment of BCAR3, BCAR1 and CRK to focal adhesions.

Similarity. Belongs to the protein-tyrosine phosphatase family. Receptor class 4 subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
P18433-5	1	yes
P18433-6	2

RefSeq proteins (27): NP_001372231, NP_001372232, NP_001372233, NP_001372234, NP_001372235, NP_001372236, NP_001372237, NP_001372239, NP_001372240, NP_001372241, NP_001372242, NP_001372243, NP_001372244, NP_001372245, NP_001372246, NP_001372247, NP_001372248, NP_001372249, NP_001372250, NP_001375249, NP_001375250, NP_001375251, NP_001375252, NP_001375253, NP_002827, NP_543030, NP_543031 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000242	PTP_cat	Domain
IPR000387	Tyr_Pase_dom	Domain
IPR003595	Tyr_Pase_cat	Domain
IPR016130	Tyr_Pase_AS	Active_site
IPR016336	Tyr_Pase_rcpt_a/e-type	Family
IPR027262	Tyr_Pase_rcpt_alpha	Family
IPR029021	Prot-tyrosine_phosphatase-like	Homologous_superfamily
IPR050348	Protein-Tyr_Phosphatase	Family

Pfam: PF00102

Enzyme classification (BRENDA)

• EC 3.1.3.48 — protein-tyrosine-phosphatase (BRENDA: 59 organisms, 501 substrates, 1326 inhibitors, 270 Km, 165 kcat entries)

Substrate kinetics (BRENDA)

70 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
4-NITROPHENYL PHOSPHATE	0.0008–148	84
6,8-DIFLUORO-4-METHYLUMBELLIFERYL PHOSPHATE	0.0039–0.862	27
P-NITROPHENYL PHOSPHATE	0.0024–10	20
DADEPYLIPQQG	0.0003–0.1	12
PHOSPHOTYROSINE	0.012–30	11
LYSOZYME	0.0003–0.012	5
MYELIN BASIC PROTEIN	0.0001–0.022	5
ACETYL-DADEPY-NH2	0.0228–0.219	4
ACETYL-DADEPYL-NH2	1.1–97.5	4
4,6,8-TRIMETHYL-2-OXO-2H-CHROMEN-7-YL DIHYDROGEN	0.02–0.156	3
SASASPYSASA	0.53–2.3	3
1-NAPHTHYL PHOSPHATE	1.19–1.88	2
3,6-FLUORESCEIN DIPHOSPHATE	15–19	2
4-METHYLUMBELLIFERYL PHOSPHATE	0.953–2.41	2
BOVINE SERUM ALBUMIN	0.0001–0.0003	2

Catalyzed reactions (Rhea)

• O-phospho-L-tyrosyl-[protein] + H2O = L-tyrosyl-[protein] + phosphate (RHEA:10684)

UniProt features (98 total): helix 28, strand 28, glycosylation site 7, turn 7, sequence conflict 6, binding site 3, modified residue 3, compositionally biased region 2, active site 2, topological domain 2, domain 2, region of interest 2, signal peptide 1, chain 1, splice variant 1, sequence variant 1, mutagenesis site 1, transmembrane region 1

Structure

Experimental structures (PDB)

1 structures by resolution:

PDB	Title	Method	Resolution (Å)
6UZT	Crystal Structure of RPTP alpha	X-RAY DIFFRACTION	1.8

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P18433-F1	82.51	0.70

Human Protein Atlas

Protein class: Enzymes, ENZYME proteins, Hydrolases, Predicted membrane proteins, Predicted intracellular proteins, Plasma proteins

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): vesicles; nucleoplasm

Antibody reliability (HPA): IH approved · IF approved

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2)

Position	Role
442	phosphocysteine intermediate
732	phosphocysteine intermediate

Ligand- & substrate-binding residues (3)

Position	Role
410	substrate
442–448	substrate
486	substrate

Post-translational modifications (3)

Type	Positions
Phosphoserine	211, 213
Phosphotyrosine	798

Glycosylation sites (7)

Type	Positions
N-linked (glcnac…) asparagine	21, 36, 68, 80, 86, 104, 124

Mutagenesis-validated functional residues (1)

Position	Phenotype
798	abolishes integrin-mediated interaction with bcar1 and bcar3 and reduces interaction between bcar1 and crk and, bcar1 and src. abolishes …

Function

Pathways and Gene Ontology

Reactome pathways

1 curated (TAS) of 8; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

8 pathways:

ID	Pathway	Evidence
R-HSA-5673001	RAF/MAP kinase cascade	curated
R-HSA-422475	Axon guidance	—
R-HSA-1266738	Developmental Biology	—
R-HSA-5683057	MAPK family signaling cascades	—
R-HSA-5684996	MAPK1/MAPK3 signaling	—
R-HSA-375165	NCAM signaling for neurite out-growth	electronic
R-HSA-9675108	Nervous system development	—
R-HSA-162582	Signal Transduction	—

MSigDB gene sets: 450 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_UP, CMYB_01, GOBP_FOCAL_ADHESION_ASSEMBLY, BIOCARTA_SRCRPTP_PATHWAY, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, REACTOME_NCAM_SIGNALING_FOR_NEURITE_OUT_GROWTH, GOBP_REGULATION_OF_CELL_JUNCTION_ASSEMBLY, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, AAAYRNCTG_UNKNOWN, GOBP_CELL_JUNCTION_ORGANIZATION, ONKEN_UVEAL_MELANOMA_UP, MORF_ATOX1, BLALOCK_ALZHEIMERS_DISEASE_UP, TGCTGAY_UNKNOWN, DACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_DN

GO Biological Process (5): signal transduction (GO:0007165), integrin-mediated signaling pathway (GO:0007229), regulation of focal adhesion assembly (GO:0051893), protein dephosphorylation (GO:0006470), dephosphorylation (GO:0016311)

GO Molecular Function (6): protein tyrosine phosphatase activity (GO:0004725), transmembrane receptor protein tyrosine phosphatase activity (GO:0005001), identical protein binding (GO:0042802), phosphoprotein phosphatase activity (GO:0004721), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (5): plasma membrane (GO:0005886), focal adhesion (GO:0005925), membrane (GO:0016020), signaling receptor complex (GO:0043235), extracellular exosome (GO:0070062)

Reactome top-level categories

6 top-level categories:

Category	Pathways
Axon guidance	1
MAPK1/MAPK3 signaling	1
Nervous system development	1
Signal Transduction	1
MAPK family signaling cascades	1
Developmental Biology	1

GO top-level categories

26 GO namespaces:

Category	Terms
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
cell surface receptor signaling pathway	1
regulation of cell-matrix adhesion	1
focal adhesion assembly	1
regulation of cell-substrate junction assembly	1
dephosphorylation	1
protein modification process	1
phosphate-containing compound metabolic process	1
phosphoprotein phosphatase activity	1
protein tyrosine phosphatase activity	1
transmembrane receptor protein phosphatase activity	1
protein binding	1
phosphatase activity	1
catalytic activity, acting on a protein	1
binding	1
catalytic activity	1
membrane	1
cell periphery	1
cell-substrate junction	1
cellular anatomical structure	1
protein-containing complex	1
extracellular vesicle	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 3 of 16 annotations. The rest are phylogenetic / computational / electronic (IEA).

3 experimentally-supported GO terms:

GO term	NS	Evidence
extracellular exosome	CC	high-throughput assay
signaling receptor complex	CC	direct assay
identical protein binding	MF	physical interaction

Protein interactions and networks

STRING

showing 15 of 942 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PTPRA	PTS	Q03393	935
PTPRA	FN1	P02751	672
PTPRA	HCK	P08631	596
PTPRA	DUSP3	P51452	571
PTPRA	UBOX5	O94941	555
PTPRA	SRC	P12931	536
PTPRA	LZTS3	O60299	518
PTPRA	FYN	P06241	502
PTPRA	ACP1	P24666	475
PTPRA	VPS16	Q9H269	466
PTPRA	DUSP23	Q9BVJ7	448
PTPRA	MRPS26	Q9BYN8	447
PTPRA	GNRH2	O43555	441
PTPRA	NCBP3	Q53F19	430
PTPRA	CDC14A	Q9UNH5	425

IntAct

Human interaction partners of PTPRA in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

19 partners by confidence:

Partner	Interaction type	MIscore	Records
GRB2	physical association	0.940	8
SRC	association	0.730	8
LGALS1	association	0.640	2
PTPRE	association	0.640	1
EGFR	physical association	0.630	3
CYB561	association	0.530	1
LGALS8	association	0.530	1
SP4	association	0.530	1
CNTN1	physical association	0.460	2
LMNB1	physical association	0.400	1
GABARAPL2	physical association	0.370	1
HSPB1	physical association	0.370	1
PTGER4	physical association	0.370	1
SHC1	physical association	0.370	1
RCCD1	association	0.350	1
SLC2A4	association	0.350	1
UVRAG	association	0.350	1
HUNK	physical association	0.000	1
LCOR	physical association	0.000	1

BioGRID (208 interactions; top human partners by supporting records): GRB2 (Affinity Capture-MS; 19 records), PTPRE (Affinity Capture-MS; 7 records), LGALS8 (Affinity Capture-MS; 4 records), SRC (Affinity Capture-Western; 4 records), CYB561 (Affinity Capture-MS; 3 records), EGFR (Two-hybrid; 3 records), FCN1 (Affinity Capture-MS; 3 records), ASNSD1 (Affinity Capture-MS; 2 records), BAIAP2 (Proximity Label-MS; 2 records), BASP1 (Proximity Label-MS; 2 records), CCDC88A (Proximity Label-MS; 2 records), CKB (Affinity Capture-MS; 2 records), CSE1L (Affinity Capture-MS; 2 records), DENND4A (Affinity Capture-MS; 2 records), ERBB2 (Affinity Capture-Western; 2 records)

SIGNOR signaling

showing 11 of 13 signaling interactions:

A	Effect	B	Mechanism
SRC	“up-regulates activity”	PTPRA	phosphorylation
PTPRA	down-regulates	KCNB1	dephosphorylation
PTPRA	up-regulates	FYN	dephosphorylation
PTPRA	“up-regulates activity”	SRC	dephosphorylation
PTPRA	“down-regulates activity”	PTPRA	dephosphorylation
PRKCD	“up-regulates activity”	PTPRA	phosphorylation
MARCHF9	“down-regulates quantity by destabilization”	PTPRA	ubiquitination
PTPRA	“down-regulates activity”	VPS33B	dephosphorylation
PTPRA	up-regulates	SRC	dephosphorylation
PTPRA	“up-regulates activity”	FYN	dephosphorylation
PTPRA	“down-regulates activity”	LYN	dephosphorylation

Protein complexes (CORUM) (1)

Experimentally-characterized complexes this protein is a subunit of (★ = the complex contains a known drug target).

1 complexes by size:

Complex	Subunits	Members
PTPRA homodimer	1	PTPRA

Disease & clinical

Genetic variants

Variant evidence for PTPRA: 197 ClinVar records (6 pathogenic / likely pathogenic); 7 GWAS associations. Per-variant detail is on Sugi Variant.

ClinVar

197 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	5
Uncertain significance	146
Likely benign	11
Benign	5

Top pathogenic / likely-pathogenic (6)

Showing all 6 pathogenic / likely-pathogenic ClinVar records, ranked by ClinVar review status (expert panel → multiple submitters → single submitter), then by number of submitting labs.

Variant ID	HGVS	Classification	Review	Submitters
4072036	NM_022575.4(VPS16):c.1955dup (p.Thr653fs)	Pathogenic	criteria provided, single submitter	1
1804074	NM_022575.4(VPS16):c.1988_1989insG (p.Asn663fs)	Likely pathogenic	criteria provided, single submitter	1
2430290	NM_022575.4(VPS16):c.2272-18C>A	Likely pathogenic	criteria provided, single submitter	1
4072035	NM_022575.4(VPS16):c.1818+2T>G	Likely pathogenic	criteria provided, single submitter	1
4072396	NM_022575.4(VPS16):c.2066dup (p.Gln690fs)	Likely pathogenic	criteria provided, single submitter	1
4852185	NM_022575.4(VPS16):c.2170_2171del (p.Lys724fs)	Likely pathogenic	criteria provided, single submitter	1

Per-variant reference — Sugi Variant

Explore PTPRA’s pathogenic and likely-pathogenic variants individually — each with its ClinVar classification and conditions, applied ACMG criteria (ClinGen expert panel, where curated), the calibrated in-silico predictors (AlphaMissense, REVEL, SaProt, conservation), gnomAD frequency, and the predictor-disagreement QC signal — on Sugi Variant.

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 25 predictions of 2,540):

Position(s)	Effect	Δscore	Sites
20:2923205–2923206	acceptor_loss	1.0000	6
20:2975113	donor_gain	1.0000
20:2988336–2988337	acceptor_loss	1.0000	6
20:2988463	donor_gain	1.0000
20:3005127	donor_gain	1.0000
20:3007342–3007343	acceptor_loss	1.0000	6
20:3015843	acceptor_gain	1.0000
20:3017801	acceptor_gain	1.0000
20:3017804	acceptor_gain	1.0000
20:3017815	acceptor_loss	1.0000

AlphaMissense

2,941 missense substitutions predicted likely pathogenic (of 5,294 scored), across 590 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
M338	9	0.993	1.000
M550	9	0.971	0.998
M774	9	0.914	0.999
M709	9	0.903	0.998
M327	9	0.900	0.999
M461	9	0.893	0.990
M420	9	0.870	0.999
M620	9	0.870	0.997
D410	8	1.000	1.000
D759	8	0.999	1.000
H441	8	0.998	1.000
N269	8	0.997	1.000
S443	8	0.997	1.000
F493	8	0.995	1.000
N265	8	0.994	1.000
D377	8	0.994	0.999
D278	8	0.991	0.999
F801	8	0.988	1.000
F411	8	0.987	1.000
F423	8	0.987	1.000

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

1 prognostic cancer types:

Cancer	Prognostic	p-value
Kidney Renal Clear Cell Carcinoma (TCGA)	favorable	1.23e-05

Disease associations

OMIM: gene MIM:176884 | disease phenotypes: MIM:619291

GenCC curated gene-disease

Mondo (1): dystonia 30 (MONDO:0025691)

GWAS associations

7 associations:

Study	Trait	p-value
GCST90002387_314	Immature fraction of reticulocytes	1e-15
GCST90002393_21	Monocyte count	1e-15
GCST90002398_220	Neutrophil count	1e-12
GCST90002385_130	High light scatter reticulocyte count	1e-11
GCST90002407_507	White blood cell count	1e-11
GCST90002386_235	High light scatter reticulocyte percentage of red cells	1e-10
GCST008156_43	Hip circumference adjusted for BMI	4e-6

EFO canonical traits (from GWAS)

4 canonical traits:

EFO ID	Trait name
EFO:0008039	BMI-adjusted hip circumference
EFO:0007986	reticulocyte count
EFO:0005091	monocyte count
EFO:0004833	neutrophil count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3918 (SINGLE PROTEIN)

PharmGKB: 1 entry (CPIC guideline: no)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: catalytic receptor — Receptor tyrosine phosphatase (RTP) family

Binding affinities (BindingDB)

80 measured of 108 human assays (111 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
(S)-4-((S)-1-amino-3-(4-(difluoro(phosphono)methyl)phenyl)-1-oxopropan-2-ylamino)-3-(2-(4-(difluoro(phosphono)methyl)phenyl)acetamido)-4-oxobutanoic acid	KI	24 nM
2-(N-(4-(2-acetamido-3-(4-(5-chloro-3-hydroxy-2-(methoxycarbonyl)phenoxy)butylamino)-3-oxopropyl)-2-ethylphenyl)-1-carboxyformamido)benzoic acid	KI	40 nM
Aminobenzoic acid analog 5	KI	65 nM
2-(4-(2-acetamido-3-(4-(1-carboxy-N-(2-carboxyphenyl)formamido)-3-ethylphenyl)propanamido)butoxy)-6-hydroxybenzoic acid	KI	73 nM
2-[(4-{2-Acetylamino-2-[4-(3-hydroxy-2-nitro-phenoxy)-butylcarbamoyl]-ethyl}-2-ethyl-phenyl)-oxalyl-amino]-benzoic acid	KI	120 nM
1:1 mixture of diastereomers	KI	380 nM
(1S,2R,4aS,6aS,6bR,8aR,10R,11R,12aR,12bR,14bS)-10,11-dihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid	IC50	810 nM
2-[(4-{2-Acetylamino-2-[4-(3-hydroxy-2-methylcarbamoyl-phenoxy)-butylcarbamoyl]-ethyl}-2-ethyl-phenyl)-oxalyl-amino]-benzoic acid	KI	830 nM
4-[4-(2-Acetylamino-3-{4-[(2-carboxy-phenyl)-oxalyl-amino]-3-ethyl-phenyl}-propionylamino)-butoxy]-2-hydroxy-biphenyl-3-carboxylic acid methyl ester	KI	840 nM
2-carboxy(2-ethyl-4-{2-methylcarboxamido-2-[4-(2-methyloxycarbonylphenoxy)butylcarbamoyl]ethyl}phenyl)carboxamidobenzoic acid	KI	860 nM
{4-[2-BENZYL-3-METHOXY-2-(METHOXYCARBONYL)-3-OXOPROPYL]PHENYL}SULFAMIC ACID	IC50	900 nM
CHEMBL2316902	IC50	1400 nM
3beta-hydroxyurs-12-en-28-oic acid	IC50	1900 nM
CHEMBL2316907	IC50	1900 nM
3-(carboxyformamido)-5-(4-(carboxymethoxy)phenyl)thiophene-2-carboxylic acid	KI	2500 nM
6-[4-(2-Acetylamino-3-{4-[(2-carboxy-phenyl)-oxalyl-amino]-3-ethyl-phenyl}-propionylamino)-butoxy]-3-bromo-2-hydroxy-benzoic acid methyl ester	KI	2600 nM
6-hydroxy-3-iodo-1-methyl-2-[3-[[2-oxo-2-(4-thiophen-3-ylanilino)acetyl]amino]phenyl]indole-5-carboxylic acid	IC50	2900 nM	US-9522881: Hydroxyindole carboxylic acid based inhibitors for oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2)
CHEMBL2316906	IC50	2900 nM
4-(9,10-dioxo-4-(phenylamino)-5,8,9,10-tetrahydroanthracen-1-ylamino)benzenesulfonic acid	IC50	3600 nM
8-phenyl-1-thia-4,8-diazaspiro[4.5]decane-3-carboxylic acid	IC50	4000 nM
2-amino-3-(3,5-dibromo-4-hydroxyphenyl)propanoic acid	IC50	4600 nM
2-(2,3-dihydro-1H-pyrrolo[3,4-b]quinolin-3-yl)acetic acid	IC50	5500 nM
6-(3,3-Diphenyl-propyl)-2-(oxalyl-amino)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid	KI	5800 nM
[2,6-Dibromo-4-(6-bromo-benzo[b]naphtho[2,3-d]thiophen-11-yl)-phenoxy]-acetic acid	IC50	7900 nM
(4aS,6aS,6bR,10S,12aR,14bS)-10-Hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-octadecahydro-2H-picene-4a-carboxylic acid	IC50	8800 nM
(R)-2-[2,6-Dibromo-4-(6-bromo-benzo[b]naphtho[2,3-d]furan-11-yl)-phenoxy]-3-phenyl-propionic acid	IC50	11000 nM
3-(4-Benzyl-piperazin-1-ylmethyl)-pyrimido[5,4-e][1,2,4]triazine-5,7-diamine	IC50	12000 nM
CHEMBL365490	IC50	15900 nM
3-(4-Biphenyl-4-ylmethyl-piperazin-1-ylmethyl)-pyrimido[5,4-e][1,2,4]triazine-5,7-diamine	IC50	16000 nM
6-(Oxalyl-amino)-1H-indole-7-carboxylic acid	KI	20000 nM
(S)-1-Ammonium-2-phenyl-ethanephosphonic acid anion	KI	27500 nM
3-Diethylaminomethyl-pyrimido[5,4-e][1,2,4]triazine-5,7-diamine	IC50	28000 nM
10,13-dimethyl-17-(2-(6-thioxo-3H-purin-9(6H)-yl)acetyl)-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one	IC50	35000 nM
2-(3-(dihydroxymethyl)naphthalen-2-ylamino)-2-oxoacetic acid	KI	37000 nM
2-oxalylamino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid	KI	41000 nM
5-iodo-2-(oxaloamino)benzoic acid	KI	49000 nM
5-(4-Isobutyl-phenyl)-3-(oxalyl-amino)-thiophene-2-carboxylic acid	KI	50000 nM
2-amino-3-(6-nitro-1H-indol-3-yl)propanoic acid	IC50	51000 nM
2-(carboxyformamido)-6-oxo-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid	KI	52000 nM
2-(carboxyformamido)-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylic acid	KI	53000 nM
6-(carboxyformamido)-1H-indole-5-carboxylic acid	KI	56000 nM
2-(carboxyformamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylic acid	KI	59000 nM
5-(4-(benzyloxy)phenyl)-3-(carboxyformamido)thiophene-2-carboxylic acid	KI	65000 nM
2-(hydroxyimino)-3-(quinolin-4-yl)propanoic acid	IC50	72000 nM
2-hydroxy-3-(pyridin-2-yl)propanoic acid	IC50	88000 nM
3-(Oxalyl-amino)-5-phenyl-thiophene-2-carboxylic acid	KI	90000 nM
4-(Oxalyl-amino)-[2,3’]bithiophenyl-5-carboxylic acid	KI	90000 nM
3-(Oxalyl-amino)-5-(4-phenoxy-phenyl)-thiophene-2-carboxylic acid	KI	93000 nM
2-(carboxyformamido)-5,7-dihydro-4H-thieno[2,3-c]thiopyran-3-carboxylic acid	KI	100000 nM
2-amino-3-(5-oxo-5H-benzo[a]phenoxazin-10-yl)propanoic acid	IC50	108000 nM

ChEMBL bioactivities

27 potent at pChembl≥5 of 50 total, top 26 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.62	Ki	24	nM	CHEMBL326115
7.19	Ki	65	nM	CHEMBL116605
7.14	Ki	73	nM	CHEMBL117699
6.92	Ki	120	nM	CHEMBL116692
6.80	Ki	160	nM	CHEMBL68125
6.64	Ki	230	nM	CHEMBL117496
6.42	Ki	380	nM	CHEMBL55243
6.33	Ki	470	nM	CHEMBL325029
6.08	Ki	840	nM	CHEMBL326829
6.08	Ki	830	nM	CHEMBL116901
6.07	Ki	860	nM	CHEMBL116744
6.05	IC50	900	nM	CHEMBL379000
6.05	Ki	900	nM	CHEMBL55799
5.96	Ki	1100	nM	CHEMBL303333
5.92	Ki	1200	nM	CHEMBL65097
5.82	Ki	1500	nM	CHEMBL67740
5.58	Ki	2600	nM	CHEMBL326830
5.44	IC50	3600	nM	CHEMBL1254283
5.40	IC50	4000	nM	CHEMBL1253342
5.34	IC50	4600	nM	CHEMBL1253341
5.26	IC50	5500	nM	CHEMBL1253920
5.26	IC50	5500	nM	CHEMBL1254283
5.26	IC50	5500	nM	CHEMBL1253313
5.24	Ki	5800	nM	CHEMBL138106
5.09	IC50	8100	nM	CHEMBL1253313
5.09	IC50	8100	nM	CHEMBL1253920

PubChem BioAssay actives

27 with measured affinity, of 290 total; 23 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(3S)-4-[[(2S)-1-amino-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-3-[[2-[4-[difluoro(phosphono)methyl]phenyl]acetyl]amino]-4-oxobutanoic acid	209830: Inhibitory constant against T cell protein tyrosine phosphatase	ki	0.0240	uM
2-[4-[2-acetamido-3-[4-(3-hydroxy-2-methoxycarbonylphenoxy)butylamino]-3-oxopropyl]-2-ethyl-N-oxaloanilino]benzoic acid	209825: Inhibitory constant of compound against T cell protein tyrosine phosphatase was determined	ki	0.0650	uM
2-[4-[[2-acetamido-3-[4-(2-carboxy-N-oxaloanilino)-3-ethylphenyl]propanoyl]amino]butoxy]-6-hydroxybenzoic acid	209830: Inhibitory constant against T cell protein tyrosine phosphatase	ki	0.0730	uM
2-[4-[2-acetamido-3-[4-(3-hydroxy-2-nitrophenoxy)butylamino]-3-oxopropyl]-2-ethyl-N-oxaloanilino]benzoic acid	209830: Inhibitory constant against T cell protein tyrosine phosphatase	ki	0.1200	uM
2-[2-[(E)-3-amino-3-oxoprop-1-enyl]-4-[2-(methanesulfonamido)-3-oxo-3-(pentylamino)propyl]-N-oxaloanilino]benzoic acid	209829: Inhibitory constant of compound against T cell protein tyrosine phosphatase was determined	ki	0.1600	uM
2-[4-[2-acetamido-3-[4-(5-chloro-3-hydroxy-2-methoxycarbonylphenoxy)butylamino]-3-oxopropyl]-2-ethyl-N-oxaloanilino]benzoic acid	209830: Inhibitory constant against T cell protein tyrosine phosphatase	ki	0.2300	uM
2-[4-[2-acetamido-3-[[5-[[(1S)-1-carboxy-3-methylsulfanylpropyl]amino]-5-oxopentyl]amino]-3-oxopropyl]-2-ethyl-N-oxaloanilino]benzoic acid	209830: Inhibitory constant against T cell protein tyrosine phosphatase	ki	0.3800	uM
2-[4-[(2S)-3-[4-(3-hydroxy-2-methoxycarbonylphenoxy)butylamino]-3-oxo-2-(prop-2-enoxycarbonylamino)propyl]-N-oxaloanilino]benzoic acid	209830: Inhibitory constant against T cell protein tyrosine phosphatase	ki	0.4700	uM
2-[4-[2-acetamido-3-[4-[3-hydroxy-2-(methylcarbamoyl)phenoxy]butylamino]-3-oxopropyl]-2-ethyl-N-oxaloanilino]benzoic acid	209830: Inhibitory constant against T cell protein tyrosine phosphatase	ki	0.8300	uM
2-[4-[2-acetamido-3-[4-(3-hydroxy-2-methoxycarbonyl-4-phenylphenoxy)butylamino]-3-oxopropyl]-2-ethyl-N-oxaloanilino]benzoic acid	209830: Inhibitory constant against T cell protein tyrosine phosphatase	ki	0.8400	uM
2-[4-[2-acetamido-3-[4-(2-methoxycarbonylphenoxy)butylamino]-3-oxopropyl]-2-ethyl-N-oxaloanilino]benzoic acid	209830: Inhibitory constant against T cell protein tyrosine phosphatase	ki	0.8600	uM
2-[4-[2-acetamido-3-oxo-3-(pentylamino)propyl]-2-ethyl-N-oxaloanilino]benzoic acid	209829: Inhibitory constant of compound against T cell protein tyrosine phosphatase was determined	ki	0.9000	uM
[4-(2-benzyl-3-methoxy-2-methoxycarbonyl-3-oxopropyl)phenyl]sulfamic acid	269827: Inhibition HPTPA	ic50	0.9000	uM
2-[[4-[2-acetamido-3-oxo-3-(pentylamino)propyl]naphthalen-1-yl]-oxaloamino]benzoic acid	209829: Inhibitory constant of compound against T cell protein tyrosine phosphatase was determined	ki	1.1000	uM
2-[4-[2-acetamido-3-oxo-3-(pentylamino)propyl]-N-oxalo-2-propan-2-ylanilino]benzoic acid	209829: Inhibitory constant of compound against T cell protein tyrosine phosphatase was determined	ki	1.2000	uM
2-[4-[2-acetamido-3-oxo-3-(pentylamino)propyl]-2-(2-hydroxyethyl)-N-oxaloanilino]benzoic acid	209829: Inhibitory constant of compound against T cell protein tyrosine phosphatase was determined	ki	1.5000	uM
2-[4-[2-acetamido-3-[4-(4-bromo-3-hydroxy-2-methoxycarbonylphenoxy)butylamino]-3-oxopropyl]-2-ethyl-N-oxaloanilino]benzoic acid	209830: Inhibitory constant against T cell protein tyrosine phosphatase	ki	2.6000	uM
4-[(4-anilino-9,10-dioxo-5,8-dihydroanthracen-1-yl)amino]benzenesulfonic acid	513952: Inhibition of human cytoplasmic protein tyrosine phosphatase A assessed as change in enzyme activity at pH 7	ic50	3.6000	uM
8-phenyl-1-thia-4,8-diazaspiro[4.5]decane-3-carboxylic acid	513952: Inhibition of human cytoplasmic protein tyrosine phosphatase A assessed as change in enzyme activity at pH 7	ic50	4.0000	uM
2-amino-3-(3,5-dibromo-4-hydroxyphenyl)propanoic acid	513952: Inhibition of human cytoplasmic protein tyrosine phosphatase A assessed as change in enzyme activity at pH 7	ic50	4.6000	uM
5-[(2-hydroxynaphthalen-1-yl)diazenyl]naphthalene-2-sulfonic acid	513950: Inhibition of human cytoplasmic protein tyrosine phosphatase A assessed as change in enzyme activity at pH 5	ic50	5.5000	uM
2-(2,3-dihydro-1H-pyrrolo[3,4-b]quinolin-3-yl)acetic acid	513950: Inhibition of human cytoplasmic protein tyrosine phosphatase A assessed as change in enzyme activity at pH 5	ic50	5.5000	uM
6-(3,3-diphenylpropyl)-2-(oxaloamino)-5,7-dihydro-4H-thieno[2,3-c]pyridine-3-carboxylic acid	209824: Inhibitory effect against T cell protein tyrosine phosphatase (TC-PTP) using p-nitrophenyl phosphate as substrate at pH 7.0	ki	5.8000	uM

CTD chemical–gene interactions

43 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression, decreases methylation	2
sodium arsenite	decreases expression	2
Resveratrol	affects cotreatment, increases expression, decreases expression	2
Atrazine	affects cotreatment, increases expression	2
aristolochic acid I	decreases expression	1
geldanamycin	increases expression	1
methylmercuric chloride	increases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, decreases expression, increases abundance	1
trichostatin A	decreases expression	1
beta-lapachone	increases expression	1
alpha-cobratoxin	decreases expression, decreases reaction	1
nickel sulfate	decreases expression	1
methacrylaldehyde	affects cotreatment, decreases expression, increases abundance	1
CGP 52608	affects binding, increases reaction	1
2-(oxalylamino)benzoic acid	decreases activity	1
Vorinostat	decreases expression	1
Acrolein	affects cotreatment, decreases expression, increases abundance	1
Air Pollutants	decreases expression, increases abundance, affects cotreatment	1
Arsenates	affects cotreatment, increases expression	1
Vehicle Emissions	increases abundance, increases expression	1
Benzo(a)pyrene	affects methylation	1
Caffeine	affects phosphorylation	1
Cocaine	decreases expression	1
Hydrogen Peroxide	affects expression	1
Ivermectin	decreases expression	1
Mecamylamine	decreases expression, decreases reaction	1
Methylnitronitrosoguanidine	decreases expression	1
Nicotine	decreases expression, decreases reaction	1
Ozone	affects cotreatment, decreases expression, increases abundance	1

ChEMBL screening assays

41 unique, capped per target: 41 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1037598	Binding	Inhibition of PTPRA	Knowledge-based characterization of similarity relationships in the human protein-tyrosine phosphatase family for rational inhibitor design. — *J Med Chem*

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E1N8	HyCyte U-937 KO-hPTPRA	Cancer cell line	Male

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

showing 60 of 300 trials:

NCT	Phase	Status	Title
NCT00211796	Phase 4	COMPLETED	Divalproex Sodium ER in Adult Autism
NCT00391261	Phase 4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT00409747	Phase 4	COMPLETED	Minocycline to Treat Childhood Regressive Autism
NCT00576732	Phase 4	COMPLETED	A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder
NCT00844753	Phase 4	COMPLETED	Atomoxetine, Placebo and Parent Management Training in Autism
NCT01028820	Phase 4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01098383	Phase 4	UNKNOWN	Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders
NCT01333865	Phase 4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	Phase 4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	Phase 4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02069977	Phase 4	UNKNOWN	Study to Evaluate the Efficacy and Safety of Aripiprazole
NCT02096952	Phase 4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02199925	Phase 4	UNKNOWN	An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum
NCT02235467	Phase 4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02255565	Phase 4	COMPLETED	Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study
NCT02940574	Phase 4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	Phase 4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	Phase 4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	Phase 4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	Phase 4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	Phase 4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	Phase 4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	Phase 4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	Phase 4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	Phase 4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	Phase 4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	Phase 4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	Phase 4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	Phase 4	RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT07770152	Phase 4	NOT_YET_RECRUITING	Semaglutide in Youth With Autism Spectrum Disorder
NCT00036231	Phase 3	TERMINATED	Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction
NCT00036244	Phase 3	COMPLETED	Synthetic Human Secretin in Children With Autism
NCT00065884	Phase 3	UNKNOWN	Valproate Response in Aggressive Autistic Adolescents
NCT00065962	Phase 3	COMPLETED	Secretin for the Treatment of Autism
NCT00252603	Phase 3	COMPLETED	Galantamine Versus Placebo in Childhood Autism
NCT00346736	Phase 3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00352248	Phase 3	COMPLETED	Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder
NCT00352352	Phase 3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00355329	Phase 3	COMPLETED	Randomized Control Trial of Using Tongue Acupuncture in Autistic Spectrum Disorder Using PET Scan for Clinical Correlation
NCT00498173	Phase 3	COMPLETED	Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism
NCT00541346	Phase 3	COMPLETED	A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms
NCT00549562	Phase 3	COMPLETED	Study of Paliperidone ER in Adolescents and Young Adults With Autism
NCT00584480	Phase 3	COMPLETED	Pilot Study of the Effect of Hyperbaric Oxygen Treatment on Behavioral and Biomarker Measures in Children With Autism
NCT00655174	Phase 3	COMPLETED	Fluvoxamine and Sertraline in Childhood Autism - Does SSRI Therapy Improve Behaviour and/or Mood?
NCT00881452	Phase 3	COMPLETED	A Trial of CM-AT in Children With Autism
NCT00912691	Phase 3	COMPLETED	A Trial of CM-AT in Children With Autism- Open Label Extension Study
NCT01302964	Phase 3	COMPLETED	Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
NCT01706523	Phase 3	TERMINATED	Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
NCT01740869	Phase 3	COMPLETED	Autologous Bone Marrow Stem Cells for Children With Autism Spectrum Disorders
NCT01825798	Phase 3	COMPLETED	Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)
NCT01911442	Phase 3	COMPLETED	Lurasidone Pediatric Autism Study
NCT01914393	Phase 3	COMPLETED	Pediatric Open-Label Extension Study
NCT01972074	Phase 3	COMPLETED	Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder
NCT02410902	Phase 3	COMPLETED	A Trial of CM-AT in Children With Autism With All Levels of FCT (The Blum Study)
NCT02649959	Phase 3	ACTIVE_NOT_RECRUITING	An Open Label Study of CM-AT for the Treatment of Children With Autism
NCT02654743	Phase 3	COMPLETED	Open Label of Clinical Trial of Sulforaphane in Children With Autism
NCT02985749	Phase 3	COMPLETED	A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder
NCT03197922	Phase 3	COMPLETED	Treatment of Encopresis in Children With Autism Spectrum Disorders
NCT03504917	Phase 3	TERMINATED	A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
NCT03553875	Phase 3	TERMINATED	Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for PTPRA across ~30M SureChEMBL compounds — explore on Sugi Predict.